SonoVol, founded in Durham, United States, is dedicated to developing fully-automated benchtop ultrasound platforms aimed at lowering the barrier of entry for biologists in preclinical screening and in vivo data acquisition. Their core mission is to enhance the efficiency and accuracy of preclinical research in the pharmaceutical, biotech, government, and academic sectors. The company's flagship products include the Vega® automated ultrasound system and VesselVue® microbubble contrast agents, which enable researchers to rapidly determine tumor characteristics and vascular density through advanced robotic motion control.

Notable figures in SonoVol's journey include its founders and key investors who have supported its growth and integration into the broader market. The company has achieved significant milestones, including becoming part of Revvity, which has expanded its reach and resources. SonoVol's impact is evident in its contribution to more standardized and reliable preclinical research methodologies, ultimately accelerating advancements in disease research and drug development.